Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity
Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity
复制标题
DOI：
10.1136/jim-2016-000062
复制
发表时间：
2016-06-01
影响因子：
2.6
通讯作者：
Alkim, Canan
中科院分区：
文献类型：
--
作者：
Boga, Salih;Alkim, Huseyin;Alkim, Canan
白介素33的特异性配体ST2被认为是炎症过程的生物标志蛋白，在溃疡性结肠炎(UC)中有过表达。我们的目的是研究血清ST2水平与UC和克罗恩病(CD)的临床、内窥镜和组织病理学活动评分之间的潜在关系。测定143例炎症性肠病(IBD)患者(UC 83例，CD 60例)、50例健康人(HC)和32例肠易激综合征(IBS)患者血清ST2水平。IBD组血清ST2水平(56.8(41.9-87.2)pg/m L)显著高于HC和IBS组(30.7(20.2-54.3)pg/m L，P
ST2, a specific ligand of interleukin 33, was described as a biomarker protein of inflammatory processes and overexpression of ST2 in ulcerative colitis (UC) was shown previously. We aimed to investigate the potential relationship of serum ST2 levels with the clinical, endoscopic and histopathological activity scores in UC and Crohn's disease (CD). Serum ST2 levels were determined in 143 patients with inflammatory bowel disease (IBD) (83 UC and 60 CD), in 50 healthy controls (HC), and in 32 patients with irritable bowel syndrome (IBS). Serum ST2 levels were elevated in IBD (56.8 (41.9-87.2) pg/mL) compared to HC and IBS (30.7 (20.2-54.3), p